Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

In the first study, titled "The Anti-tumor Response of BPM31510 is Associated with Immune Cell Regulation in the Tumor Microenvironment," researchers showed that BPM31510 significantly increases ...

The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16 ... known ability to increase RPF in order to create an exposure-response model for phase 2 dose ...

Science Forum in collaboration with the department of science organized Valedictory ceremony of science week- 'Sciencia' at ...

Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow ( ...

Top-line results from registration-directed SUMMIT, PEAK and APEX trials expected in 2025 Phase 1 trial initiated for CGT-4859, a reversible, potent, selective, FGFR2 inhibitor SUMMIT and APEX ...

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

A return to the White House for Donald Trump will include major defense policy changes but also budget shifts and reform ...

Hinton moved to the University of Toronto in 1987 and began attracting young researchers who wanted to study neural networks.

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

B.D. Memorial Jr School, in collaboration with the Indian Museum, recently hosted a non-competitive, collaborative event to ...